Recent changes

Activity feed

Jun 2026Biohacking Risk Ledger

Reviewed · Biohacking & Risk · Clinical practice

Jun 2026Cellular Reprogramming

Emerging evidence · Longevity Science · Preclinical

Jun 2026Brain-Computer Interfaces

Emerging evidence · Cybernetics · Early human

Jun 2026Personalized RNA Medicine

Clinical · Future Pharma · Clinical practice

Jun 2026Epigenetic Clocks

Reviewed · Genetic Modification · Early human

Jun 2026Longevity Pharma Pipeline

Needs citations · Future Pharma · Early human

Reviewed pages

Date	Page	Portal	Status	Risk	Summary
Jun 2026	Biohacking Risk Ledger	Biohacking & Risk	Reviewed	Low	Self-experimentation should be judged by reversibility, measurement quality, downside planning, and evidence strength.
Jun 2026	Cellular Reprogramming	Longevity Science	Emerging evidence	High	Partial reprogramming aims to restore youthful cell function without erasing identity or triggering uncontrolled growth.
Jun 2026	Brain-Computer Interfaces	Cybernetics	Emerging evidence	High	BCIs connect neural activity to computers, prosthetics, and communication systems, with medical restoration leading enhancement.
Jun 2026	Personalized RNA Medicine	Future Pharma	Clinical	Moderate	Programmable RNA platforms can compress the path from molecular insight to tailored therapy, especially for rare or rapidly changing targets.
Jun 2026	Epigenetic Clocks	Genetic Modification	Reviewed	Low	DNA methylation clocks estimate biological age and may become trial tools, but they are not a substitute for health outcomes.
Jun 2026	Longevity Pharma Pipeline	Future Pharma	Needs citations	Moderate	Aging-targeted pharma is moving from supplement claims toward indication-led trials, combination logic, and prevention endpoints.
Jun 2026	Gene Editing Platforms	Genetic Modification	Clinical	High	CRISPR, base editing, prime editing, and epigenetic editing expand what medicine can rewrite, regulate, or silence.
May 2026	Cybernetic Prosthetics	Cybernetics	Reviewed	Moderate	Next-generation prosthetics combine robotics, neural control, sensory feedback, and adaptive software.
May 2026	Senolytics and Senomorphics	Longevity Science	Emerging evidence	Moderate	Drugs that remove or quiet senescent cells could reduce inflammatory aging signals, but benefits depend heavily on context.
May 2026	Regenerative Organ Platforms	Frontier Biotech	Emerging evidence	High	Organoids, bioprinting, xenotransplantation, and perfusion systems are converging on the bottleneck of organ replacement.
Apr 2026	Synthetic Biology	Frontier Biotech	Emerging evidence	Moderate	Engineered cells and biological circuits could sense disease, manufacture therapies, and adapt inside the body.